Stock listing

BMV:SRPT Sarepta Therapeutics, Inc. Acciones

Mexican listing (BMV) of Sarepta Therapeutics, Inc. · home listing NASDAQ:SRPT

Follow Sarepta Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SRPT

$17.73 USD +0.63 (+3.7%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SRPT

Since Jul 6, 2026 -7.6% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$17.12 – $17.83 USDOct 19, 2026
Volume
2.33M sharesOct 19, 2026
Market value
$1.87B USDAt the close on Oct 19, 2026 · price × 105.6M shares outstanding
Sarepta Therapeutics, Inc. logo
Ticker
BMV:SRPT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BMV
Currency
MXN

What changed lately

Calls

Replays

  • Sarepta Therapeutics (NASDAQ:SRPT) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 5:30 PM ET

    Watch Transcript

  • Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Sarepta Therapeutics (NASDAQ:SRPT) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Oct 14, 2026

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Sep 30, 2026

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Sep 25, 2026

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Sep 24, 2026

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Sep 8, 2026

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 31, 2026

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Aug 5, 2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

Jul 30, 2026

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

Jul 27, 2026

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Jul 22, 2026

All Sarepta Therapeutics, Inc. news

Decks

Sarepta Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
40 in the last 12 months · 231 in all · newest Oct 14, 2026 · oldest 2019
Calls
17 calls with a replay · 17 with a transcript · latest Aug 5, 2026
Decks
36 decks · latest Aug 5, 2026

Where Sarepta Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SRPT · Home listingNASDAQUnited StatesUSD
B3:S1RP34B3BrazilBRL
gettex:AB3AgettexGermanyEUR
LS Exchange:A1J1BHLS ExchangeGermanyEUR
Tradegate:AB3ATradegateGermanyEUR
BMV:SRPT · This pageBMVMexicoMXN
Lang & Schwarz:A1J1BHLang & SchwarzGermanyEUR
LSE:0L35LSEUnited KingdomUSD
Frankfurt:AB3AFrankfurtGermanyEUR
BOATS:SRPTBOATSUnited StatesUSD
Milan:1SRPTMilanItalyEUR
BIVA:SRPTBIVAMexicoMXN
Dusseldorf:AB3ADusseldorfGermanyEUR
Hamburg:AB3AHamburgGermanyEUR
Munich:AB3AMunichGermanyEUR
Stuttgart:AB3AStuttgartGermanyEUR
BX Swiss:AB3ABX SwissSwitzerlandCHF

Log in to ask 6ix AI your own questions about Sarepta Therapeutics, Inc.